美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

255.86

-1.1400-0.44%

盘后：255.860.00000.00%19:37 EDT

成交量：40.22万

成交额：1.03亿

市值：302.96亿

市盈率：-69.09

高：257.61

开：255.22

低：250.00

收：257.00

数据加载中...

总览公司新闻公告

百济神州6月5日成交额为3977.19万美元

@望京博格：欧美医药企业有很多市值超万亿，中国药企只有恒瑞医药、百济神州超3000亿元，未来成长空间很大

百济神州6月4日成交额为7447.90万美元

估值31.3亿元！维立志博提交港股IPO，百济神州已退回LAG-3抗体

富时罗素公布2025年6月季检结果，富时中国A50指数成分股纳入江苏银行，剔除长城汽车；百济神州、伊利股份、上汽集团、赛

百济神州6月3日成交额为6547.38万美元

百济神州6月2日成交额为4431.37万美元

新景智源与百济神州签署授权协议，以支持百济神州开发下一代细胞治疗药物

投资界综合

百济神州在2025年ASCO年会上展示百悦泽®SEQUOIA研究最新结果

百济神州(06160)5月31日因受限制股份单位获归属而发行55.69万股

是的，你没看错，创新药一哥它变“新”了！

AMAC医药制造指数上涨0.72%，前十大权重包含百济神州等

百济神州5月29日成交额为7751.10万美元

恒瑞和百济神州两款靶向HER2重磅新药获批上市

天风证券：维持百济神州“买入”评级，泽布替尼放量稳定

天风证券给予百济神州买入评级，2025Q1首次实现季度GAAP净利润转正，泽布替尼放量稳定

每日经济新闻

百济神州首次披露 2 款实体瘤管线临床数据

Insight数据库

百济神州(06160)因受限制股份单位获归属而发行约7.93万股

Biotech的“二次创业”：NewCo模式能否跑出下一个“百济神州”？

21世纪经济报道

百济神州5月27日成交额为7583.02万美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ONC/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":255.86,"timestamp":1749240000000,"preClose":257,"halted":0,"volume":402215,"hourTrading":{"tag":"盘后","latestPrice":255.86,"preClose":255.86,"latestTime":"19:37 EDT","volume":9594,"amount":2454826.56,"timestamp":1749253071067},"delay":0,"floatShares":75624000,"shares":118408800,"eps":-3.70325,"marketStatus":"休市中","change":-1.14,"latestTime":"06-06 16:00:00 EDT","open":255.22,"high":257.61,"low":250,"amount":102785962.807,"amplitude":0.029611,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":257,"preHourTrading":{"tag":"盘前","latestPrice":259.99,"preClose":257,"latestTime":"08:01 EDT","volume":221,"amount":56107.18165,"timestamp":1749211287445},"postHourTrading":{"tag":"盘后","latestPrice":255.86,"preClose":255.86,"latestTime":"19:37 EDT","volume":9594,"amount":2454826.56,"timestamp":1749253071067},"volumeRatio":1.558219123925793,"impliedVol":0.4005,"impliedVolPercentile":0.1308},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75624000,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":1.558219123925793,"shares":118408800,"dividePrice":0,"high":257.61,"amplitude":0.029611,"preClose":257,"low":250,"week52Low":141.31,"pbRate":"8.66","psRate":"7.26","week52High":287.88,"institutionHeld":0,"latestPrice":255.86,"eps":-3.70325,"divideRate":0,"volume":402215,"delay":0,"ttmEps":-3.70325,"open":255.22,"prevYearClose":184.71,"prevWeekClose":245.58,"prevMonthClose":245.58,"prevQuarterClose":272.17,"fiveDayClose":245.58,"twentyDayClose":235.94,"sixtyDayClose":249.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541081881","title":"百济神州6月5日成交额为3977.19万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541081881","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541081881?lang=zh_cn&edition=fundamental","pubTime":"2025-06-06 11:46","pubTimestamp":1749181591,"startTime":"0","endTime":"0","summary":"美东时间2025年6月5日，百济神州成交额为3977.19万美元，成交额较昨日减少46.60%，当日成交量为15.44万股。百济神州于2025年6月5日跌0.49%，报257.0美元，该股过去5个交易日涨4.18%，年初至今涨39.14%，过去60日涨4.59%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250606114632a49c4fd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250606114632a49c4fd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2541025830","title":"@望京博格：欧美医药企业有很多市值超万亿，中国药企只有恒瑞医药、百济神州超3000亿元，未来成长空间很大","url":"https://stock-news.laohu8.com/highlight/detail?id=2541025830","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541025830?lang=zh_cn&edition=fundamental","pubTime":"2025-06-05 17:02","pubTimestamp":1749114120,"startTime":"0","endTime":"0","summary":"6月5日消息，知名基金博主@望京博格 表示，欧美医药企业有很多市值超过万亿， 中国药企只有恒瑞医药、百济神州超3000亿元，药明康德、瀚森制药、信达生物也只是刚刚迈过千亿市值门槛。中国药企与全球大药企的市值相比天壤之别，这也是未来的成长空间。@望京博格 认为，创新药毛利率很高，不比新能源汽车出口赚的少，这是一个非常大的市场。\n　　以下是全文：\n\n\nMACD金叉信号形成，这些股涨势不错！\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：常福强","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-06-05/doc-ineyzhci6455321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","LU2328871848.SGD","LU1328615791.USD","LU0307460666.USD","LU0405327148.USD","LU0405327494.USD","LU0588546209.SGD","LU2488822045.USD","BK0196","LU1064130708.USD","BK1588","BK1161","688235","BK0012","BK0239","01276","BK0028","LU1969619763.USD","BK0060","600276","LU2148510915.USD","BK0183","BK4139","BK4526","ONC","BK1500","LU1064131003.USD","BK1583","BK1191","06160"],"gpt_icon":0},{"id":"2541012417","title":"百济神州6月4日成交额为7447.90万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541012417","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541012417?lang=zh_cn&edition=fundamental","pubTime":"2025-06-05 11:41","pubTimestamp":1749094887,"startTime":"0","endTime":"0","summary":"美东时间2025年6月4日，百济神州成交额为7447.90万美元，成交额较昨日增加13.75%，当日成交量为28.78万股。百济神州于2025年6月4日涨2.6%，报258.27美元，该股过去5个交易日涨7.43%，年初至今涨39.82%，过去60日涨6.43%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605114135a6fb20f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605114135a6fb20f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2540662150","title":"估值31.3亿元！维立志博提交港股IPO，百济神州已退回LAG-3抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=2540662150","media":"Medaverse","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540662150?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 20:36","pubTimestamp":1749040570,"startTime":"0","endTime":"0","summary":"6月4日，维立志博提交港股上市申请，摩根士丹利和中信证券担任联席保荐人。维立志博于2012年11月成立，并自2014年5月起开始业务营运。根据百济神州提供的终止通知所指，百济神州协议其后已于2025年5月18日终止。百济神州并无披露亦无计划披露终止百济神州协议的原因。于该终止后，维立志博已重新获得开发、生产及商业化LBL-007的全部全球权利。目前核心管线包括PD-L1/4-1BB双抗、CD3/GPRC5D TCE LBL-034、CD3/MUC16 TCE LBL-033、LAG3抗体LBL-007。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604205723a6fa4d82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604205723a6fa4d82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","BK4526","ONC","BK4614","YANG","BK4139"],"gpt_icon":0},{"id":"2540030198","title":"富时罗素公布2025年6月季检结果，富时中国A50指数成分股纳入江苏银行，剔除长城汽车；百济神州、伊利股份、上汽集团、赛","url":"https://stock-news.laohu8.com/highlight/detail?id=2540030198","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540030198?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 16:35","pubTimestamp":1749026153,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["82333","601127","BK4581","ONC","06160","LU0890818403.SGD","600887","BK0224","LU0588546209.SGD","LU0821914370.USD","LU2476274308.USD","LU0307460666.USD","LU0650527681.SGD","02333","IE00B0169N27.USD","BK0070","LU1997245177.USD","BK4139","LU1997245094.SGD","BK0015","UWM","LU1655091616.SGD","IE00BYV24P56.USD","IWM","TZA","159593","IWN","RWM","BK4534","BK0184","BK1583","GWLLY","TNA","LU2506952253.HKD","600104","BK0130","SRTY","600919","688235","601633","LU2148510915.USD","IWO","TWM","BK0175","IE00B543WZ88.USD","MNQmain","IE00B5MMRT66.SGD","300124","BK0188","BK0020"],"gpt_icon":0},{"id":"2540080254","title":"百济神州6月3日成交额为6547.38万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540080254","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540080254?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 11:40","pubTimestamp":1749008427,"startTime":"0","endTime":"0","summary":"美东时间2025年6月3日，百济神州成交额为6547.38万美元，成交额较昨日增加47.75%，当日成交量为26.06万股。百济神州于2025年6月3日涨2.35%，报251.72美元，该股过去5个交易日涨5.63%，年初至今涨36.28%，过去60日涨1.88%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604114035a49939e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604114035a49939e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2540468957","title":"百济神州6月2日成交额为4431.37万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540468957","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540468957?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 11:35","pubTimestamp":1748921711,"startTime":"0","endTime":"0","summary":"美东时间2025年6月2日，百济神州成交额为4431.37万美元，成交额较昨日减少55.42%，当日成交量为18.08万股。百济神州于2025年6月2日涨0.14%，报245.93美元，该股过去5个交易日涨1.86%，年初至今涨33.14%，过去60日跌4.3%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603113515a6f7f412&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603113515a6f7f412&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2540712451","title":"新景智源与百济神州签署授权协议，以支持百济神州开发下一代细胞治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2540712451","media":"投资界综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540712451?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 09:10","pubTimestamp":1748913000,"startTime":"0","endTime":"0","summary":"北京时间2025年6月3日，新景智源生物科技（苏州）有限公司，一家专注于实体肿瘤TCR-T免疫细胞治疗药物的研发企业，宣布与百济神州签署了非*许可协议, 将向百济神州授权一项公司自主研发的抗原特异性的TCR分子的权益，用于百济神州开发基于iPSC平台的下一代通用型细胞治疗药物。百济神州将拥有使用该授权TCR分子开发下一代细胞治疗产品，并进行商业化的权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603092104a6f7c91c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603092104a6f7c91c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK1588","LU0307460666.USD","BK1583","ONC","BK1161","LU0588546209.SGD","06160","BK1500","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2540712062","title":"百济神州在2025年ASCO年会上展示百悦泽®SEQUOIA研究最新结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2540712062","media":"百济神州","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540712062?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 09:01","pubTimestamp":1748912462,"startTime":"0","endTime":"0","summary":"许多CLL一线治疗研究都排除了伴有高危疾病特征的患者人群，但百济神州在SEQUOIA研究中纳入了这些患者。百悦泽安全性特征与既往研究结果一致，未发现新的安全信号。2024年，美国预计新增约20,700例CLL病例3。凭借SEQUOIA研究队列1的结果，百悦泽单药治疗已在全球许多国家获得监管批准用于TN CLL患者。百悦泽全球临床开发项目迄今已在全球30个国家和地区超过35项试验中入组约7,100例","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603090537a49762b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603090537a49762b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","06160","ONC","688235","BK4526"],"gpt_icon":0},{"id":"2540755875","title":"百济神州(06160)5月31日因受限制股份单位获归属而发行55.69万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2540755875","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540755875?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 08:34","pubTimestamp":1748824464,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，2025年5月30日，因根据股权计划授出的受限制股份单位获归属(本公司董事除外)而发行1.42万股普通股。2025年5月31日，因根据股权计划授出的受限制股份单位获归属(本公司董事除外)而发行55.69万股普通股。因合资格参与者(本公司董事除外)于2025年5月1日至2025年5月30日期间行使购股权而发行20.61万股普通股，每股发行价为7.37美元。因合资格参与者(本公司董事除外)于2025年5月1日至2025年5月30日期间行使购股权而发行7.5万股普通股，每股发行价为0.5美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1300166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","LU1969619763.USD","BK1161","BK0239","06160","LU0588546209.SGD","BK4526","688235","BK1500","LU0307460666.USD","LU2328871848.SGD","BK1583","ONC","BK4139"],"gpt_icon":0},{"id":"2539063732","title":"是的，你没看错，创新药一哥它变“新”了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2539063732","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539063732?lang=zh_cn&edition=fundamental","pubTime":"2025-05-31 07:31","pubTimestamp":1748647907,"startTime":"0","endTime":"0","summary":"然而2024年世界经合组织发布的全球最低税规则彻底改变了游戏规则。与此同时，欧盟对“避税天堂”的监管压力与日俱增，企业声誉风险上升。2024年百济神州总收入272.14亿元人民币，同比增长56.2%，在第三季度首次突破10亿美元大关。卫材新药“莱博雷生”国内获批上市剑指自免“药王”！百奥泰“乌司奴单抗”获FDA批准上市同日两款！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531074039a6f3f0df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531074039a6f3f0df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK0239","688235","159992"],"gpt_icon":0},{"id":"2539278273","title":"AMAC医药制造指数上涨0.72%，前十大权重包含百济神州等","url":"https://stock-news.laohu8.com/highlight/detail?id=2539278273","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539278273?lang=zh_cn&edition=fundamental","pubTime":"2025-05-30 22:15","pubTimestamp":1748614537,"startTime":"0","endTime":"0","summary":"金融界5月30日消息，上证指数低开低走，AMAC医药制造指数 上涨0.72%，报4317.68点，成交额782.2亿元。数据统计显示，AMAC医药制造指数近一个月上涨7.85%，近三个月上涨10.03%，年至今上涨8.59%。从指数持仓来看，AMAC医药制造指数十大权重分别为：恒瑞医药、片仔癀、云南白药、科伦药业、新和成、长春高新、复星医药、上海莱士、百济神州、万泰生物。从AMAC医药制造指数持仓样本的行业来看，医药卫生占比98.02%、主要消费占比1.98%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/30221550785925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["399233","LU2328871848.SGD","LU0307460666.USD","LU0588546209.SGD","BK1588","BK1161","688235","BK0239","LU1969619763.USD","159938","BK1574","BK1515","BK4139","BK4526","ONC","09939","BK1500","BK1583","06160"],"gpt_icon":0},{"id":"2539211919","title":"百济神州5月29日成交额为7751.10万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539211919","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539211919?lang=zh_cn&edition=fundamental","pubTime":"2025-05-30 11:33","pubTimestamp":1748576036,"startTime":"0","endTime":"0","summary":"美东时间2025年5月29日，百济神州成交额为7751.10万美元，成交额较昨日增加71.21%，当日成交量为31.47万股。百济神州于2025年5月29日涨2.61%，报246.68美元，该股过去5个交易日涨4.31%，年初至今涨33.55%，过去60日跌4.13%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530113357a6f2adba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530113357a6f2adba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2539239361","title":"恒瑞和百济神州两款靶向HER2重磅新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2539239361","media":"医药魔方","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539239361?lang=zh_cn&edition=fundamental","pubTime":"2025-05-29 15:04","pubTimestamp":1748502294,"startTime":"0","endTime":"0","summary":"在亚组分析中，瑞康曲妥珠单抗的疗效在不同亚组患者中保持一致，无论患者是否接受过抗HER2 TKI治疗，或者是否存在基线脑转移。2023年6月，百济神州在ASCO大会公布了IIb期HERIZON-BTC-01研究结果。2名患者因不良事件而停用泽尼达妥单抗，7名患者发生严重TRAE。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529151510a490e9d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529151510a490e9d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","LU0307460666.USD","06160","BK1161","688235","BK1588","LU2328871848.SGD","BK1583","LU1969619763.USD","ONC","BK1500"],"gpt_icon":0},{"id":"2539233793","title":"天风证券：维持百济神州“买入”评级，泽布替尼放量稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2539233793","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539233793?lang=zh_cn&edition=fundamental","pubTime":"2025-05-29 14:21","pubTimestamp":1748499708,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["III","BK0239","03347","BK4526","688235","06160","BK1583","601162","LU2328871848.SGD","LU1969619763.USD","BK1141","BK1500","ONC","LU0588546209.SGD","BK1588","BK0276","BK4134","LU0307460666.USD","BK1576","BK4139","BK1161"],"gpt_icon":0},{"id":"2539282682","title":"天风证券给予百济神州买入评级，2025Q1首次实现季度GAAP净利润转正，泽布替尼放量稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2539282682","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539282682?lang=zh_cn&edition=fundamental","pubTime":"2025-05-29 11:14","pubTimestamp":1748488440,"startTime":"0","endTime":"0","summary":"天风证券05月29日发布研报称，给予百济神州（688235.SH，最新价：223.7元）买入评级。评级理由主要包括：1）各费用率逐季降低，降本增效，实现首次季度GAAP净利润盈利；2）泽布替尼美国正常季度波动，看好全年销售放量；3）预计将有多个概念验证里程碑读出，核心管线研发进程顺利。风险提示：政策变动风险、全球市场风险、研发进度不及预期风险。（文章来源：每日经济新闻）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052911200995065fba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052911200995065fba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2539725282","title":"百济神州首次披露 2 款实体瘤管线临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2539725282","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539725282?lang=zh_cn&edition=fundamental","pubTime":"2025-05-29 09:08","pubTimestamp":1748480893,"startTime":"0","endTime":"0","summary":"2025 年 ASCO 大会即将召开，百济神州有 23 篇摘要入选。本届大会上，百济神州将首次披露其两款在研实体瘤管线的临床数据，分别为BG-68501、BG-C9074。百济神州曾表示，CDK2 抑制剂 BG-68501 可与其自主研发的 CDK4 抑制剂形成补充，有望改善目前 CDK4/6 抑制剂在特定乳腺癌患者中的治疗效果，并强化百济在乳腺癌和其它实体瘤领域的早期研发管线。截至 2025 年 1 月 22 日，55 例晚期肿瘤患者接受了 BG-C9074 单药治疗，包括 25 例卵巢癌，16 例乳腺癌，10 例胆管癌，4 例其他类型肿瘤患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529113758a490b4a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250529113758a490b4a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2539400494","title":"百济神州(06160)因受限制股份单位获归属而发行约7.93万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2539400494","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539400494?lang=zh_cn&edition=fundamental","pubTime":"2025-05-29 07:59","pubTimestamp":1748476757,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)公布，2025年5月28日，因根据股权计划授出的受限制股份单位获归属(公司董事除外)而发行约7.93万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1298900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","ONC","LU0588546209.SGD","BK1161","688235","BK4139","BK1588","BK1583","LU2328871848.SGD","BK0239","BK1500","06160","LU0307460666.USD","BK4526"],"gpt_icon":0},{"id":"2538422346","title":"Biotech的“二次创业”：NewCo模式能否跑出下一个“百济神州”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2538422346","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538422346?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 17:41","pubTimestamp":1748425280,"startTime":"0","endTime":"0","summary":"NewCo模式或被视为打破僵局的重要一环。这也不是岸迈生物首次达成的NewCo合作。为此，不少药企选择从现实出发采用NewCo的方式“出海”。另据医药魔方数据库，2024年，参与到国内创新药产品NewCo模式的海外资本超过40家，参与2次及以上NewCo模式投资的海外资本则超过10家。NewCo的“阿喀琉斯之踵”尽管NewCo模式优势显著，但其成功高度依赖合作双方的战略契合度与执行能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052818072797685d6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052818072797685d6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2538410173","title":"百济神州5月27日成交额为7583.02万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2538410173","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538410173?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 11:36","pubTimestamp":1748403401,"startTime":"0","endTime":"0","summary":"美东时间2025年5月27日，百济神州成交额为7583.02万美元，成交额较昨日增加83.37%，当日成交量为31.73万股。百济神州于2025年5月27日跌1.29%，报238.31美元，该股过去5个交易日涨2.12%，年初至今涨29.02%，过去60日跌12.32%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528113648a6efb87a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528113648a6efb87a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盘前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-06-06","current":-77.688492,"percent":0.003891,"low":-78.0724,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"high":-19.234246,"avg":-35.988763,"sd":13.690738,"marketCap":30482322820},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820}],"updateTime":1749410626281}}}